LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS)
("COMPASS"), a biotechnology company dedicated to accelerating patient access to
evidence-based innovation in mental health, today announced the publication of a
new paper in Pyschopharmacology, which showed the results of a retrospective
study that evaluates the potential of its AI technologies to support
investigational COMP360 psilocybin treatment in treatment-resistant depression
(TRD). The paper was published on August 22, 2023.
The peer-reviewed paper shows the AI model has the potential to predict outcomes
of the investigational COMP360 psilocybin treatment in people with TRD up to 12
weeks after treatment using recordings taken during the integration session 24
hours post administration. Further research and studies are required to validate
this model and to evaluate its capabilities to predict responder status pre-
treatment.
Using a large language model, COMPASS created a machine learning algorithm that
assessed the emotional sentiment of 101 English speaking participants from the
company's recent randomized double-blind phase 2b study in TRD. The sentiment
scores, as measured by valence (happiness to sadness) and arousal (intensity of
emotion), were then used in the second stage of the machine algorithm to predict
patient response as measured by the Montgomery-Asberg Depression Rating Scale
(MADRS) at three weeks and three months post-drug administration. This model
yielded a cross-validated accuracy of 85% and 88% at the three and twelve-week
timepoints, respectively. The Area Under the Curve (AUC) results were comparable
with values of 88% and 85% at the three and twelve-week timepoints.
"These results are exciting because they signal that we could potentially use AI
technology to predict long-term patient response in the emerging field of
psilocybin treatment," said Kabir Nath, CEO of COMPASS Pathways. "We believe
this could also support the delivery of more personalized care in the long-term
for people suffering from TRD."
"Our goal is to use technology to move clinical psychology toward precision
medicine," said Greg Ryslik, Chief Technology Officer at COMPASS. "By using
Natural Language Processing (NLP) to identify key linguistic and speech-based
digital biomarkers, we have the opportunity to further understand the
presentation of TRD and help provide a deeper understanding of treatment-
resistant depression as a whole if unique patterns between individuals emerge."
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to
accelerating patient access to evidence-based innovation in mental health. Our
focus is on improving the lives of those who are suffering with mental health
challenges and who are not helped by current treatments. We are pioneering the
development of a new model of psilocybin treatment, in which our proprietary
formulation of synthetic psilocybin, COMP360, is administered in conjunction
with psychological support. COMP360 has been designated a Breakthrough Therapy
by the U.S. Food and Drug Administration (FDA) and has received Innovative
Licensing and Access Pathway (ILAP) designation in the UK for treatment-
resistant depression (TRD).
We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in
TRD, the largest randomized, controlled, double-blind psilocybin treatment
clinical program ever conducted. Previously, we completed a phase 2b study with
top line data showing a statistically significant (pÂ